Business Wire

Xlife Sciences AG: Transaction with Baliopharm AG

Share

Xlife Sciences AG has reached a licensing agreement with the biotech firm Baliopharm AG, located in Basel. According to the agreement, Xlife Sciences AG will receive 10% of future income from license fees of Baliopharm AG. The Basel-based company is a leader in innovative antibody therapies for the treatment of acute and chronic inflammatory diseases.

According to the concluded licensing agreement with Baliopharm AG, Xlife Sciences AG will receive 10% of all future licensing income up to a maximum of 300 million euros. This applies to the company's entire line of active ingredients. Xlife Sciences AG thus participates directly in the future success and innovative strength of a leading biotech company in the field of antibody therapies with this transaction.

On the 18th of December, Baliopharm AG received the approval to start Phase I of medical drug Atrosimab for the treatment of Non-Alcoholic SteatoHepatitis (NASH) by the Australian Healthcare Administration. NASH is the most frequent chronic liver disease. The Global Liver Institute estimates that there are more than 115 million people affected globally by NASH. According to the Institute, this number could double by 2030. In Germany, 1.5 to 2 million patients have at least a mild form of NASH. Under more severe circumstances, the disease can lead to irreversible liver damage (liver cirrhosis) and cannot be treated therapeutically. In this way, Baliopharm AG views this as a huge market.

About Xlife Sciences AG
Xlife Sciences AG is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets by supporting researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage. For more information, please visit: www.xlifesciences.ch

Language:

English

Company:

Xlife Sciences AG

Klausstrasse 19

8008 Zürich

Switzerland

Phone:

0041 44 385 84 60

E-mail:

info@xlifesciences.ch

Internet:

www.xlifesciences.ch

ISIN:

CH0461929603

WKN:

A2PK6Z

Listed:

Regulated Unofficial Market in Frankfurt, Munich

EQS News ID:

1159182

Contact information

For media inquiries
Oliver R. Baumann
CEO Xlife Sciences AG
Tel. +41 44 385 84 60
oliver.baumann@xlifesciences.ch

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Owl Labs inleder samarbete med Ingram Micro för ökad distribution av Meeting Owl Pro i Europa26.1.2021 09:00:00 CETPressmeddelande

Owl Labs, den prisbelönta ledaren inom avanceradteknologi och tjänster för samarbete genom videokonferenser, tillkännager idag ett samarbete med Ingram Micro, världens största distributör och leverantör av tekniska tjänster och lösningar. Det nya distributionsavtalet ökar Owl Labs räckvidd i Europa och stärker företagets närvaro på de viktiga europeiska marknaderna. Owl Labs samarbete med Ingram Micro ger nu företaget möjlighet att utöka räckvidden och tillgången till dess prisbelönta huvudprodukt, Meeting Owl Pro, via det centraliserade distributionslagret i Straubing, Tyskland. Från distributionslagret stöds sedan alla 28 länder i försörjningskedjan till 17 olika distributionscenter placerade runt om i Europa. Ingram Micro arbetar med en varierad bas av återförsäljare och med fler än 2 000 av världens mest erkända varumärken inom IT- och mobilteknologi. Med den snabba anpassningen till hybrid- och distansarbete är det viktigare än någonsin att upprätthålla effektiv kommunikation och

MyHeritage lanserar färgåterställningsfunktion för att få nytt liv i blekta färgfoton26.1.2021 08:46:00 CETPressmeddelande

MyHeritage, den ledande globala tjänsten för att upptäcka ditt förflutna och stärka din framtid, har idag meddelat om lanseringen av färgåterställning för blekta färgfoton. Färgåterställningen återupplivar de autentiska färgerna i blekta foton med exceptionella resultat och utgör en stor förstärkning av MyHeritages avancerade serie av fotoverktyg. Detta pressmeddelande använder multimedia. Se den fullständiga versionen här: https://www.businesswire.com/news/home/20210125005984/sv/ MyHeritage lanserar färgåterställningsfunktion för att få nytt liv i blekta färgfoton (Photo: Business Wire) Färgåterställning är idealisk för gamla färgfoton från 1950- till 1990-talet, där kemin i pappersfoton som lagrats i album inte tål tidens prövningar och färgerna har bleknat eller blivit gulaktiga. Tekniken för färgåterställning licensierades uteslutande från DeOldify, skapad av djupinlärningsexperterna Jason Antic och Dana Kelley och integrerades i MyHeritage. Det återställer ett fotografis originalf

Credence MedSystems Receives a Strategic Investment From One of the World’s Leading Pharmaceutical Companies26.1.2021 07:07:00 CETPress release

Credence MedSystems announced today that Novartis has made a strategic investment in the Company. The investment will advance ongoing development and scaling of Credence’s innovative drug delivery systems, with an initial focus on the Credence Companion® Safety Syringe System. With the investment in Credence, Novartis seeks to support its patients, caregivers, and healthcare professionals by enhancing the safety and user experience during administration of Novartis injectable medications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210125005138/en/ The Credence Companion allows pharmaceutical manufacturers to provide critical usability and safety features to their end-users. At the completion of the injection, the user receives end-of-dose cues indicating that the full dose has been delivered, and the needle automatically retracts into the syringe barrel. The enhanced usability can contribute to improved adherence, while

AGCO Announces Organizational Update25.1.2021 22:31:00 CETPress release

AGCO (NYSE: AGCO), a global leader in the design, manufacture and distribution of agricultural machinery and solutions, today announced intended changes and recent additions to its senior leadership team to further increase customer focus and strengthen investment in precision agriculture and digital solutions to maximize stakeholder value. Robert Crain will be the Senior Vice President leading the newly formed Customer Experience team charged with delivering the best end-to-end customer experience in the industry. Seth Crawford has joined the senior team in the new role of Senior Vice President, Precision Ag and Digital to reinforce AGCO’s commitment to delivering industry-leading, smart farming solutions. Following a successful, 22-year tenure at Deere & Company, Mr. Crawford joined AGCO in 2019 to lead its Fuse Connected Services and Technology division. Additionally, other members of the senior team will assume worldwide responsibility for AGCO’s core brands to maximize brand value

Mytheresa Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares25.1.2021 22:15:00 CETPress release

MYT Netherlands Parent B.V. (“Mytheresa” or the “Company”), the parent company of Mytheresa Group GmbH, today announced the closing of its initial public offering of 17,994,117 American Depositary Shares (“ADSs”), representing 17,994,117 ordinary shares, including the full exercise by the underwriters of their option to purchase 2,347,058 additional ADSs, representing 2,347,058 ordinary shares, at a public offering price of $26.00 per ADS. The Company sold 14,233,823 ADSs in the offering and its sole shareholder sold 3,760,294 ADSs in the offering, including 586,764 ADSs sold by the Company and 1,760,294 ADSs sold by the sole shareholder pursuant to the exercise in full of the underwriters’ option to purchase additional ADSs. Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC acted as lead joint bookrunning managers and representatives of the underwriters for the offering. Credit Suisse Securities (USA) LLC and UBS Securities LLC acted as joint bookrunning managers for the offerin

UAEREP Launches Fourth Cycle and Starts Receiving Project Proposals25.1.2021 17:11:00 CETPress release

The UAE Research Program for Rain Enhancement Science (UAEREP) announced the launch of its fourth cycle at the fifth International Rain Enhancement Forum (IREF), convened virtually under the patronage of His Highness Sheikh Mansour bin Zayed Al Nahyan, UAE Deputy Prime Minister and Minister of Presidential Affairs. Submissions are open to innovative project proposals from across the globe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210125005618/en/ UAEREP’s 4th Cycle Now Open! (Graphic: AETOSWire) The program offers a grant of up to US$1.5 million, distributed over three years with a maximum annual amount of $550,000 for each winning research proposal in the rain enhancement field. Over its past three cycles, the program has provided grants to nine ground-breaking projects that covered different fields related to rain enhancement and weather modification research. Interested academic institutions, research centers and ot

PPG Donates Coatings, Sealants to Help Restore Douglas C-54 Skymaster Aircraft25.1.2021 17:02:00 CETPress release

PPG (NYSE:PPG) today announced that it recently supplied coatings and sealants to help restore a 74-year-old, four-engine transport aircraft – the Douglas C-54 Skymaster, serial number 56498. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210125005599/en/ PPG today announced that it recently supplied coatings and sealants to help restore a 74-year-old, four-engine transport aircraft – the Douglas C-54 Skymaster, serial number 56498. (Photo: Business Wire) Manufactured in 1945, the aircraft was used by the U.S. Army Air Force as a workhorse to transport medical supplies, troops and military equipment during World War II, the Korean War and the Vietnam War. It left military service in 1973 and was flown as a sprayer from 1975 to 1985. After its first restoration was completed in 2002, the aircraft was flown to England to be featured in a film about the Berlin Airlift. The film was cancelled, and the C-54 Skymaster sat exposed

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom